Abstract
Cancer stem cells (CSCs) express specific antigens associated with stemness. CSCs derived from solid tumors are resistant to various anticancer agents. Given that the spectrum of drug resistance in CSCs is not well understood, literature searches using various keyword combinations were performed to investigate whether CSCs residing in solid cancers are innately resistant to both lipophilic (e.g., P-glycoprotein substrates) and hydrophilic (e.g., non-P-glycoprotein substrates) substances. Current literature suggests that solid CSCs are more likely to acquire multidrug resistance; that is, they are significantly more likely to resist a wide variety of low-molecular-weight anticancer drugs regardless of whether these drugs are P-glycoprotein substrates. The present review further delineates emerging evidence on the use of nanomedicine to eradicate CSCs.